Effect of 5-hydroxytryptophan and melatonin supplementation on mood, sleep and cognition in adult patients with depression
Keywords:
Melatonin, 5-Hydroxytryptophan, depression, sleep quality, working memoryAbstract
5-Hydroxytryptophan (5-HTP) is a precursor to serotonin and has been used as an antidepressant. Its antidepressant potential has been evaluated under different experimental conditions with moderate results. However, it is considered to have poor pharmacokinetics and its use as an alternative treatment for mood disorders has even been questioned. This disadvantage seems to disappear when slow-release 5HTP is used. This study determined whether the combination of slow-release 5-HTP plus the combination with melatonin can reduce symptoms in patients who reported depression. This research consisted of a pre-experimental observational method (qualitative and quantitative). The participants were 20 adults between 25 and 50 years old with a previous diagnosis of depression issued by a mental health professional. Baseline values of depression, sleep quality, and working memory were measured. Subsequently, the participants were randomly assigned to the control group (n = 10) or the experimental group (n = 10). The control group only received information on general aspects of depression, while the experimental group received the combination of 100 mg of 5HTP/10 mg of melatonin for 1 month. The results indicated an improvement in mood, quality of sleep, and both verbal and visual working memory. It is concluded that the tested combination can be an effective alternative to the use of antidepressants.
Downloads
References
Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Alternative Medicine Review: a Journal of Clinical Therapeutic. 1998; 3(4):271-280. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9727088/.
Maes M, Jacobs MP, Suy E, et al. Effects of dexamethasone on the availability of L- tryptophan and on the insulin and FFA concentrations in unipolar depressed patients. Biol Psychiatry 1990; 27:854-862. doi: 10.1016/0006-3223(90)90466-f.
Sargent PA, Quested DJ, Cowen PJ. Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl). 1998; 140(1):120-2. doi: 10.1007/s002130050747. PMID: 9862411.
Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol. 1980; 10(6):603-10. doi: 10.1111/j.1365-2125.1980.tb00516.x. PMID: 6162471; PMCID: PMC1430228.
Gál EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5(3):223-39. doi: 10.1007/BF00964611. PMID: 6154900.
Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and plasma amino acids. Am J Clin Nutr. 1975; 28(6):638-47. doi: 10.1093/ajcn/28.6.638. PMID: 1093382.
den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res. 1990; 31(3):267-78. doi: 10.1016/0165-1781(90)90096-n. PMID: 2139731.
Chadwick D, Jenner P, Harris R, Reynolds EH, Marsden CD. Manipulation of brain serotonin in the treatment of myoclonus. Lancet. 1975; 6;2(7932):434-5. doi: 10.1016/s0140-6736(75)90846-6. PMID: 51240.
Matussek N, Angst J, Benkert O, Gmür M, Papousek M, Rüther E, Woggon B. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients. Adv Biochem Psychopharmacol. 1974;11(0):399-404. PMID: 4602669.
Mendlewicz J, Youdim MB. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. J Affect Disord. 1980; 2(2):137-46. doi: 10.1016/0165-0327(80)90013-0. PMID: 6448885.
Agren H, Reibring L, Hartvig P, Tedroff J, Bjurling P, Hörnfeldt K, Andersson Y, Lundqvist H, Långström B. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand. 1991; 83(6):449-55. doi: 10.1111/j.1600-0447.1991.tb05574.x. PMID: 1882697.
Jacobsen JPR, Oh A, Bangle R, Roberts WL, Royer EL, Modesto N, Windermere SA, Yi Z, Vernon R, Cajina M, Urs NM, Snyder JC, Nicholls PJ, Sachs BD, Caron MG. Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. Neuropsychopharmacology. 2019 Nov;44(12):2082-2090. doi: 10.1038/s41386-019-0400-1. Epub 2019; 29. PMID: 31035282; PMCID: PMC6898594.
Satyanarayanan SK, Su H, Lin YW, Su KP. Circadian Rhythm and Melatonin in the Treatment of Depression. Curr Pharm Des. 2018;2 4(22):2549-2555. doi: 10.2174/1381612824666180803112304. PMID: 30073921.
Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012 Oct;21(10):1503-22. doi: 10.1517/13543784.2012.711314. Epub 2012;9. PMID: 22876742.
Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013; 35(4):416-31. doi: 10.1590/1516-4446-2012-1048. Epub 2013;23. PMID: 24402217.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2):193-213. doi: 10.1016/0165-1781(89)90047-4. PMID: 2748771.
Mueller ST, Piper BJ. The Psychology Experiment Building Language (PEBL) and PEBL Test Battery. J Neurosci Methods. 2014 Jan 30;222:250-9. doi: 10.1016/j.jneumeth.2013.10.024. Epub 2013; 20. PMID: 24269254; PMCID: PMC3897935.
Kious BM, Sabic H, Sung YH, Kondo DG, Renshaw P. An Open-Label Pilot Study of Combined Augmentation with Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women. J Clin Psychopharmacol. 2017; 37(5):578-583. doi: 10.1097/JCP.0000000000000754. PMID: 28787372; PMCID: PMC5578880.
Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, Defazio G. Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. Eur J Neurol. 2020; 27(5):779-786. doi: 10.1111/ene.14179. Epub 2020 Mar 13. PMID: 32067288.
Bruni O, Angriman M, Melegari MG, Ferri R. Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders. Expert Opin Pharmacother. 2019 Dec;20(18):2257-2271. doi: 10.1080/14656566.2019.1674283. Epub 2019 22. PMID: 31638842.
Hong KB, Park Y, Suh HJ. Sleep-promoting effects of a GABA/5-HTP mixture: Behavioral changes and neuromodulation in an invertebrate model. Life Sci. 2016; 1;150:42-9. doi: 10.1016/j.lfs.2016.02.086. Epub 2016 Feb 26. PMID: 26921634.
Ioannou S, Williams AL. Preliminary fMRI findings concerning the influence of 5-HTP on food selection. Brain Behav. 2016 28;7(1):e00594. doi: 10.1002/brb3.594. PMID: 28127513; PMCID: PMC5256178.
Alghamdi BS, AboTaleb HA. Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. J Integr Neurosci. 2020; 19(2):229-237. doi: 10.31083/j.jin.2020.02.32. PMID: 32706187.
Levkovitz Y, Richter-Levin G, Segal M. Effect of 5-hydroxytryptophane on behavior and hippocampal physiology in young and old rats. Neurobiol Aging. 1994;15(5):635-41. doi: 10.1016/0197-4580(94)00058-1. PMID: 7824056.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 AVFT – Archivos Venezolanos de Farmacología y Terapéutica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
